论文部分内容阅读
Objective:The aim of our study was to evaluate the clinical efficacy and side effects of docetaxel as single chemotherapy for elderly patients with advanced non-small-cell lung cancer (NSCLC).Methods:Forty-two elderly patients with advanced NSCLC who were chemotherapy-naive were enrolled in this study.Docetaxel at the doses of 70 mg/m2 was administrated intravenously every 21 days as a cycle,each patient received 2-4 cycles.All patients were followed up until disease progressed or patients died.Results:Among 42 patients,40 could be evaluated,1 complete response (CR),9 partial response (PR),13 stable disease (SD),17 progress disease (PD).The overall response rate (CR+PR) was 35% and disease control rate (CR+PR+SD) was 57.5%.The median time to progress (TTP) was 4.2 months,median survival time was 6.1 months and 1-year survival rate was 35,8% The main toxicity was myelosuppression and decreasing platelet.Conclusion:Single agent docetaxel for elderly patients with advanced NSCLC is an efficient and well-tolerated chemotherapeutic approach with a low toxicity level.